These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28518145)

  • 21. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway.
    Li Y; Deng L; Zhao X; Li B; Ren D; Yu L; Pan H; Gong Q; Song L; Zhou X; Dai T
    J Pathol; 2018 Nov; 246(3):366-378. PubMed ID: 30043491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
    Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
    Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
    Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
    Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
    Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
    Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
    Zhang W; Wan M; Ma L; Liu X; He J
    Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
    Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
    Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
    Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
    Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
    Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
    Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
    Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
    Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway.
    Ji X; Wang Z; Sarkar FH; Gupta SV
    Anticancer Res; 2012 Jul; 32(7):2647-55. PubMed ID: 22753722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
    Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
    Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandin E2 upregulates β1 integrin expression via the E prostanoid 1 receptor/nuclear factor κ-light-chain-enhancer of activated B cells pathway in non-small-cell lung cancer cells.
    Bai X; Yang Q; Shu W; Wang J; Zhang L; Ma J; Xia S; Zhang M; Cheng S; Wang Y; Leng J
    Mol Med Rep; 2014 May; 9(5):1729-36. PubMed ID: 24584670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
    Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
    Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway.
    Chen PM; Cheng YW; Wu TC; Chen CY; Lee H
    Free Radic Biol Med; 2015 Feb; 79():127-37. PubMed ID: 25499851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.